A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

• Patients must have a confirmed diagnosis schwannomatosis by fulfilling either clinical or molecular diagnosis.

• Age ≥ 18 years. Patients \< 18 years are excluded since the safety profile of tanezumab in this population has not been determined.

• ECOG performance status ≤2 or Karnofsky ≥60%

• Participants must have normal organ and marrow function as defined per the full protocol

• The subject's weight must be≥ 45 kg at Screening.

• The subject must be willing to avoid prohibited pain medications (including non-steroidal anti-inflammatory drugs) throughout the duration of the study except as permitted per Protocol.

• Subject must have moderate to severe pain secondary to schwannomatosis, defined as Score ≥5 on the Numeric Rating Scale-11 (NRS-11) at Screening.

• Subject must have failure, intolerance, or contraindication to at least three standard of care therapies:

‣ Documented history indicating that NSAID therapy has not provided adequate pain relief or subject is unable to take NSAIDs due to contraindication or inability to tolerate.

⁃ Documented history indicating that opioid treatment has not provided adequate pain relief or subject is unwilling to take opioids, or unable to take opioids due to contraindication or inability to tolerate

⁃ Documented history indicating that neuropathic pain medications, such as gabapentin, pregabalin, or others, have not provided adequate pain relief or subject is unable to take these treatments due to contraindication or inability to tolerate.

• Female subjects of childbearing potential and at risk for pregnancy (e.g., not abstinent) must agree to use 2 highly effective methods of contraception throughout the study and for 112 days (16 weeks) after the last dose of assigned subcutaneous study medication.